Items Tagged ‘inhibitor’

June 8th, 2016

Tecentriq® Approved for Bladder Cancer


The United States Food and Drug Administration (FDA) has approved Tecentriq (atezolizumab) for the treatment of bladder cancer. Atezolizumab is an immunotherapy agent referred to as a PD-1/PD-L1 inhibitor, and is the first agent in this class to be approved for the treatment of bladder cancer. Urothelial carcinoma (formerly known as transitional cell carcinoma) is […]

View full entry

Tags: atezolizumab, Bladder Cancer, inhibitor, News, PD-1, PD-L1, Stage IV/Metastatic Bladder Cancer, Tecentriq, urothelial carcinoma